Erratum: The prenyl group contributes to activities of phytoestrogen 8-prenynaringenin in enhancing bone formation and inhibiting bone resorption in vitro (Endocrinology (2013) 154 (1202-1214) DOI: 10.1210/en.2012-2086);The prenyl group contributes to activities of phytoestrogen 8-prenynaringenin in enhancing bone formation and inhibiting bone resorption in vitro

Endocrinology

Volumn 154, Issue 3, 2013, Pages 1202-1214

  Ming, Lei Guo ^a   Lv, Xiang ^a   Ma, Xiao Ni ^a   Ge, Bao Feng ^a   Zhen, Ping ^a   Song, Peng ^a   Zhou, Jian ^a   Ma, Hui Ping ^a   Xian, Cory J ^b   Chen, Ke Ming ^a  

^a LANZHOU GENERAL HOSPITAL   (China)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

8 PRENYLNARINGENIN; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CATHEPSIN K; MESSENGER RNA; NARINGENIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PHYTOESTROGEN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; BONE MINERALIZATION; CELL DIFFERENTIATION; CONTROLLED STUDY; ESTROGEN ACTIVITY; GENE EXPRESSION; IN VITRO STUDY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; RAT;

EID: 84874616259     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.210/en.2013-1715     Document Type: Erratum

References (45)

1. Setchell KD, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: Evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr. 2003;78: 593S-609S.
2. Ullmann U, Bendik I, Flühmann B. Bonistein (synthetic genistein), a food component in development for a bone health nutraceutical. J Physiol Pharmacol. 2005;56(Suppl 1):79S-95S.
3. Atmaca A, Kleerekoper M, Bayraktar M, Kucuk O. Soy isoflavones in the management of postmenopausal osteoporosis. Menopause. 2008;15:748-757.
4. Migliaccio S, Anderson JJ. Isoflavones and skeletal health: Are these molecules ready for clinical application? Osteoporos Int. 2003;14: 361-368.
5. Wang TT, Sathyamoorthy N, Phang JM. Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis. 1996;17:271-275.
6. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998;139:4252-4263.
7. Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull. 2001;24:351-356.
8. Ming LG, Chen KM, Xian CJ. Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodeling. J Cell Physiol. 2013;228:513-521.
9. Chen XW, Garner SC, Anderson JJ. Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. Biochem Biophys Res Commun. 2002;295:417-422.
10. Bhargavan B,GautamAK,Singh D, et al. Methoxylated isoflavones, cajanin and isoformononetin, have non-estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling. J Cell Biochem. 2009;108:388-399.
11. Ma HP, Ming LG, Ge BF, et al. Icariin is more potent than genistein in promoting osteoblast differentiation and mineralization in vitro. J Cell Biochem. 2011;112:916-923.
12. Song P, Yao J, Ma HP, et al. Comparison of effects of kaempferide and anhydroicaritin on biomineralization of cultured osteoblasts. Yao Xue Xue Bao. 2012;47:890-896.
13. Milligan SR, Kalita JC, Pocock V, et al. The endocrine activities of 8-prenylnarigenin and related hop (Humulus lupulus L.) and beer flavonoids. J Clin Endocrinol Metab. 2000;85:4912-4915.
14. Effenberger KE, Johnsen SA, Monroe DG, Spelsberg TC, Westendorf JJ. Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens. J Steroid Biochem Mol Biol. 2005;96: 387-399.
15. Humpel M, Isaksson P, Schaefer O, et al. Tissue specificity of 8-prenylnaringenin: Protection from ovariectomy induced bone loss with minimal trophic effects on the uterus. J Steroid Biochem Mol Biol. 2005;97:299-305.
16. Sehmisch S, Hammer F, Christoffel J, et al. Comparison of the phytohormones genistein, resveratrol and 8-prenylnaringenin as agents for preventing osteoporosis. Planta Med. 2008;74:794-801.
17. Jung UJ, Lee MK, Jeong KS, Choi MS. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucoseregulating enzymes in C57BL/KsJ-db/db mice. J Nutr. 2004;134: 2499-2503.
18. Enoki T, Ohnogi H, Nagamine K, et al. Antidiabetic activities of chalcones isolated from a Japanese herb, Angelica keiskei. J Agric Food Chem. 2007;5:6013-6017.
19. Manthey JA, Guthrie N. Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J Agric Food Chem. 2002;50:5837-5843.
20. Wang X, Zhen L, Zhang G, Wong MS, Qin L, Yao X. Osteogenic effects of flavonoid aglycones from an osteoprotective fraction of Drynaria fortunei-An in vitro efficacy study. Phytomedicine. 2011; 18:868-872.
21. Ming LG, Chen KM, Ge BF, Zhai YK. Effects of 8-prenylnaringenin on osteoblast differentiation and biomineralization in vitro. Prog Biochem Biophys. 2011;38:433-440.
22. Yan K, Zhang C, Feng J, et al. Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells. Eur J Pharmacol. 2011;661:1-7.
23. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc fingercontaining transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108:17-29.
24. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
25. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999;96:3540-3545.
26. Zhang YH, Heulsmann A, TondraviMM,Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem. 2001;276:563-568.
27. KrumSA, Chang J, Miranda-Carboni G,WangCY. Novel functions for NFK B: Inhibition of bone formation. Nat Rev Rheumatol. 2010; 6:607-611.
28. Anderson JJ, Chen X, Boass A, et al. Soy isoflavones: No effects on bone mineral content and bone mineral density in healthy, menstruating young adult women after one year. J Am Coll Nutr. 2002;21: 388-393.
29. Register TC, Jayo MJ, Anthony MS. Soy phytoestrogens do not prevent bone loss in postmenopausal monkeys. J Clin Endocrinol Metab. 2003;88:4362-4370.
30. Bahr JM, Nakai M, Rivera A, et al. Dietary soy protein and isoflavones: Minimal beneficial effects on bone and no effect on the reproductive tract of sexually mature ovariectomized Sprague-Dawley rats. Menopause. 2005;12:165-173.
31. Bitto A, Burnett BP, Polito F, et al. Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: A comparative study with alendronate. Br J Pharmacol. 2009;156:1287-1295.
32. Yazaki K, Sasaki K, Tsurumaru Y. Prenylation of aromatic compounds, a key diversification of plant secondary metabolites. Phytochemistry. 2009;70:1739-1745.
33. Bitto A, Polito F, Squadrito F, et al. Genistein aglycone: A dual mode of action anti-osteoporotic soy isoflavone rebalancing bone turnover towards bone formation. Curr Med Chem. 2010;17:3007-3018.
34. Rong H, Boterberg T, Maubach J, et al. 8-Prenylnarigenin, the phytoestrogen in hops and beer, upregulates the function of the E-cadherin/ catenin complex in human mammary carcinoma cells. Eur J Cell Biol. 2001;80:580-585.
35. Lee JC, Kundu JK,HwangDM,NaHK,Surh YJ. Humulone inhibits phorbol ester-induced COX-2 expression in mouse skin by blocking activation of NF-K B and AP-1: IK B kinase and c-Jun-N-terminal kinase as respective potential upstream targets. Carcinogenesis. 2007;28:1491-1498.
36. Jantan I, Pisar MM, Idris MS, Taher M, Ali RM. In vitro inhibitory effect of rubraxanthone isolated from Garcinia parvifolia on platelet-activating factor receptor binding. Planta Med. 2002;68:1133- 1134.
37. Botta B, Vitali A, Menendez P, Misiti D, Delle Monache G. Prenylated flavonoids: Pharmacology and biotechnology. Curr Med Chem. 2005;12:717-739.
38. Cos P, De Bruyne T, Apers S, Vanden Berghe D, Pieters L, Vlietinck AJ. Phytoestrogens: Recent developments. Planta Med. 2003;69: 589-599.
39. Roelens F, Heldring N, Dhooge W, et al. Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alpha and beta. J Med Chem. 2006;49:7357-7365.
40. Zhang Y, Li XL, Yao XS, Wong MS. Osteogenic activities of genistein derivatives were influenced by the presence of prenyl group at ring A. Arch Pharm Res. 2008;31:1534-1539.
41. Kretzschmar G, Zierau O, Wober J, Tischer S, Metz P, Vollmer G. Prenylation has a compound specific effect on the estrogenicity of naringenin and genistein. J Steroid Biochem Mol Biol. 2010;118: 1-6.
42. Ye HY, Lou YJ. Estrogenic effects of two derivatives of icariin on human breast cancer MCF-7 cells. Phytomedicine. 2005;12:735- 741.
43. Jiang Q, Payton-Stewart F, Elliott S, et al. Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem. 2010;53:6153- 6163.
44. Simons R, Gruppen H, Bovee TF, Verbruggen MA, Vincken JP. Prenylated isoflavonoids from plants as selective estrogen receptor modulators (phytoSERMs). Food Funct. 2012;3:810-827.
45. Ming LG, Chen KM, Ge BF, Ma HP, Zhai YK. Effects of 8-prenylnarigenin on the proliferation and osteogenic differentiation of rat marrow stromal cells in vitro. Chin Pharmacol Bulletin. 2011;27:107-113.